Ban Vin Shen, Chaudhary Bedansh Roy, Allinson Kieren, Santarius Thomas, Kirollos Ramez Wadie
Division of Neurosurgery, Addenbroo-ke's Hospital, Cambridge, UK.
Depart-ment of Histopathology, Addenbrooke's Hospital, Cambridge, UK.
Neurosurgery. 2017 Jan 1;80(1):E170-E175. doi: 10.1093/neuros/nyw003.
Collision tumors are the simultaneous occurrence of more than one type of neoplasm within an anatomic space. In the pituitary sella, collision tumors are exceedingly rare, and not much is known about their etiology and prognosis.
A 74-year-old man presented with a concomitant primary pituitary lymphoma (diffuse large B-cell non-Hodgkin's lymphoma; DLBCL) and follicle-stimulating hormone (FSH)-adenoma diagnosed histologically after clinical features of apoplexy prompted urgent surgical decompression and resection. Strong immunoreactivity for FSH by the lymphoma was evident. Full-body workup demonstrated no other source for the lymphoma. He subsequently underwent 4 cycles of chemotherapy and has been in remission for over 32 months. His ophthalmoplegia at presentation persisted with no further deficits.
Four cases of collision tumors of primary pituitary lymphoma and adenoma have previously been reported. This case represents the first combination of an FSH-adenoma and a DLBCL in the literature. Prompt involvement of the hematology-oncology team contributed to the good outcome seen in this case. The putative role played by pituitary hormones in tumorigenesis is reviewed in this case report. The association is either a chance occurrence or due to the induction of lymphoma cell proliferation by the binding of FSH produced by the adenoma to the FSH receptors on the lymphoma cells.
碰撞瘤是指在一个解剖空间内同时出现一种以上类型的肿瘤。在垂体窝中,碰撞瘤极为罕见,其病因及预后情况鲜为人知。
一名74岁男性患者,因卒中临床症状促使紧急手术减压及切除,术后经组织学诊断为同时患有原发性垂体淋巴瘤(弥漫性大B细胞非霍奇金淋巴瘤;DLBCL)和促卵泡激素(FSH)腺瘤。淋巴瘤对FSH呈强免疫反应性。全身检查未发现淋巴瘤的其他来源。随后他接受了4个周期的化疗,目前已缓解超过32个月。其就诊时的眼肌麻痹持续存在,未出现进一步的功能缺损。
此前已有4例原发性垂体淋巴瘤与腺瘤碰撞瘤的病例报道。本病例是文献中首例FSH腺瘤与DLBCL的组合。血液肿瘤学团队的及时介入促成了该病例的良好预后。本病例报告回顾了垂体激素在肿瘤发生中可能扮演的角色。这种关联要么是偶然发生,要么是由于腺瘤产生的FSH与淋巴瘤细胞上的FSH受体结合,诱导淋巴瘤细胞增殖所致。